Published in Medical Letter on the CDC and FDA, July 4th, 2004
According to recent research from the United States, "Development of new anticancer drugs is a costly and risky proposition. The Developmental Therapeutics Program (DTP) of the National Cancer Institute of the United States (U.S.) facilitates the drug development process by providing access to preclinical screening services."
"Since the early 1990s, DTP has screened tens of thousands of compounds against a panel of 60 human tumor cell lines representing 9 tissue sites. At the same time, DTP began to accumulate information on the expression of molecular entities in the same...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA